Alterations in peptide levels in Parkinson's disease and incidental Lewy body disease
Alterations in peptide levels in Parkinson's disease and incidental Lewy body disease
复制标题
DOI：
10.1093/brain/119.3.823
复制
发表时间：
1996-06-01
期刊：
影响因子：
14.5
通讯作者：
Marsden, CD
中科院分区：
文献类型：
--
作者：
Fernandez, A;deCeballos, ML;Marsden, CD
采用高效液相色谱/放射免疫分析 (HPLC/RIA) 联合方法，对帕金森病患者、偶发性路易体病患者（帕金森病症状前）和匹配对照的基底神经节死后样本中的神经肽 Met 和 Leu 脑啡肽（MET-ENK、LEU-ENK）、P 物质和神经降压素的水平进行了测量。帕金森病患者尾状核和壳核中的多巴胺 (DA) 水平降低，但偶发性路易体病患者的多巴胺 (DA) 水平没有变化。帕金森病患者尾状核、壳核和黑质中 MET-ENK 水平降低。在偶发性路易体病中，尾状核和壳核中的甲硫氨酸脑啡肽水平降低。帕金森病患者壳核中的亮氨酸脑啡肽水平降低，而黑质中检测不到。偶发性路易体病中亮氨酸脑啡肽水平没有变化，但壳核有减少的趋势。帕金森病患者壳核中 P 物质水平降低。在偶发性路易体病中没有观察到 P 物质含量的显着变化，没有显着改变，但与帕金森病的变化趋于平行。偶发路易体病中基底神经节肽水平的变化通常遵循与帕金森病相似的趋势，但不太明显。这表明它们是疾病病理学的一个组成部分，而不是继发于 DA 神经元损失或长期药物治疗的结果。
The levels of the neuropeptides Met- and Leu-enkephalin (MET-ENK, LEU-ENK), substance P and neurotensin were measured by a combined high performance liquid chromatography/radioimmunoassay (HPLC/RIA) method in post-mortem samples of basal ganglia from Parkinson's disease patients, incidental Lewy body disease patients (pre-symptomatic Parkinson's disease) and matched controls. Dopamine (DA) levels were reduced in the caudate nucleus and putamen in Parkinson's disease, but unaltered in incidental Lewy body disease. The levels of MET-ENK were reduced in the caudate nucleus, putamen and substantia nigra in Parkinson's disease. Met-enkephalin levels were reduced in the caudate nucleus and in the putamen in incidental Lewy body disease. Leu-enkephalin levels were decreased in the putamen and were undetectable in the substantia nigra in Parkinson's disease. Leu-enkephalin levels were unchanged in incidental Lewy body disease, although there was a tendency to a reduction in putamen. Substance P levels were reduced in the putamen in Parkinson's disease. No significant changes in substance P content were observed in incidental Lewy body disease were not altered significantly, but tended to parallel the changes in Parkinson's disease. The changes in basal ganglia peptide levels in incidental Lewy body disease generally followed a trend similar to those seen in Parkinson's disease, but were less marked. This suggests that they are an integral part of the pathology of the illness and not secondary to DA neuronal loss or a consequence of prolonged drug therapy.